Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

8.3%

1 terminated out of 12 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

8Total
Not Applicable (2)
Early P 1 (3)
P 1 (3)

Trial Status

Unknown4
Recruiting4
Not Yet Recruiting2
Active Not Recruiting1
Terminated1

Clinical Trials (12)

Showing 12 of 12 trials
NCT05514327Not ApplicableRecruiting

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

NCT05024175Recruiting

Long-term Follow-up of Subjects Treated With CAR T Cells

NCT07338357Early Phase 1Not Yet Recruiting

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

NCT07139600Active Not Recruiting

Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy

NCT01166009Recruiting

CIBMTR Research Database

NCT06917105Phase 1Not Yet Recruiting

Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies

NCT06210243Phase 1Terminated

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

NCT06642025Early Phase 1Recruiting

EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

NCT05846347Phase 1UnknownPrimary

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

NCT04048434Not ApplicableUnknown

Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)

NCT04691349Early Phase 1UnknownPrimary

CAR-T for r/r Malignant Tumors in Children

NCT04203459Unknown

The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation

Showing all 12 trials

Research Network

Activity Timeline